Publication date: Nov 07, 2025
However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. The trial showed a progression-free survival rate of 78% at 11 months, significantly higher than the historical 46% with existing therapies, positioning iSCIB1+ as a transformative treatment option. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges.
| Concepts | Keywords |
|---|---|
| 920317technical | Analyst |
| Benefits | Clinical |
| Biotechnology | Etf |
| Immunotherapy | Financial |
| Gb | |
| Holdings | |
| Iscib1 | |
| Melanoma | |
| Scancell | |
| Sclp | |
| Stage | |
| Stock | |
| Tipranks | |
| Treatment | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | tumor |
Original Article
(Visited 12 times, 1 visits today)